Multicellular Plant Peptide Or Multicellular Plant Protein Patents (Class 930/230)
-
Patent number: 8653332Abstract: Disclosed are polypeptides, nucleic acids, and related compositions that render plants resistant to bacterial pathogens. Also disclosed are transgenic plants having the nucleic acids and resistant to bacterial pathogens.Type: GrantFiled: May 24, 2010Date of Patent: February 18, 2014Assignee: Academia SinicaInventors: Yi-Hsien Lin, Hsiang-En Huang, Teng-Yung Feng
-
Patent number: 8624085Abstract: An insect-resistant protein exhibiting a sufficient resistance to insects; an insect-resistance gene encoding the insect-resistant protein; a recombinant vector containing the insect-resistance gene; a host cell and a plant cell having the recombinant vector transfected thereinto; a transformant transformed by the insect-resistance gene and a method for producing the same; a protein recovered thereby; and an insect-resistant agent comprising them as active ingredients. In accordance with the present invention, the insect-resistant protein is derived from a plant.Type: GrantFiled: March 3, 2008Date of Patent: January 7, 2014Assignees: National Institute of Agrobiological SciencesInventors: Kotaro Konno, Naoya Wasano
-
Patent number: 8257502Abstract: The present invention relates to plant cells and plants, which are genetically modified, wherein the genetic modification leads to the reduction of the activity of a starch phosphorylating OK1 protein in comparison with corresponding wild type plant cells or wild type plants that have not been genetically modified. Furthermore, the present invention relates to means and methods for the manufacture of such plant cells and plants. Plant cells and plants of this type synthesise a modified starch. The present invention therefore also relates to the starch synthesised by the plant cells and plants according to the invention, methods for the manufacture of this starch, and the manufacture of starch derivatives of this modified starch, as well as flours containing starches according to the invention. Furthermore, the present invention relates to nucleic acid molecules, which are suitable for manufacturing plants according to the invention.Type: GrantFiled: February 23, 2011Date of Patent: September 4, 2012Assignee: Bayer Cropscience AGInventors: Claus Frohberg, Oliver Koetting, Gerhard Ritte, Martin Steup
-
Patent number: 8007592Abstract: The present invention relates to plant cells and plants, which are genetically modified, whereby the genetic modification leads to an increase in the activity of a starch-phosphorylating OK1 protein in comparison to the corresponding wild type plant cells or wild type plants that have not been genetically modified. In addition, the present invention concerns means and methods for the manufacture of such plant cells and plants. These types of plant cells and plants synthesise a modified starch. Therefore, the present invention also concerns the starches synthesised from the plant cells and plants according to the invention, methods for manufacturing these starches, and the manufacture of starch derivatives of these modified starches, as well as flours containing starches according to the invention. Furthermore, the present invention also relates to nucleic acids, coding starch-phosphorylating OK1 proteins, vectors, host cells, plant cells, and plants containing such nucleic acid molecules.Type: GrantFiled: May 5, 2010Date of Patent: August 30, 2011Assignee: Bayer Cropscience AGInventors: Claus Frohberg, Oliver Koetting, Gerhard Ritte, Martin Steup
-
Patent number: 7439347Abstract: Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: GrantFiled: October 13, 2005Date of Patent: October 21, 2008Assignee: Tripep ABInventor: Matti Sällberg
-
Patent number: 6486302Abstract: The invention provides isolated Hm2 nucleic acids, and their encoded proteins. The present invention provides methods and compositions relating to altering Hm2 concentration and/or composition of plants. The invention further provides expression cassettes, host cells, transgenic plants, and antibody compositions. Also, the invention provides methods of identifying plant transformation by survival of transformed plant cells or tissues on a cyclic tetrapeptide toxin. The invention further provides methods of imparting disease resistance to plants susceptible to fungal pathogens, which utilize cyclic tetrapeptide toxins.Type: GrantFiled: January 24, 2001Date of Patent: November 26, 2002Assignee: Pioneer Hi-Bred International, Inc.Inventors: Steven P. Briggs, Gurmukh Johal, Dilbag Singh Multani
-
Patent number: 6066482Abstract: Essentially pure acyltransferase is provided which is functional to catalyze reaction to form sugar esters. Also provided is isolated gene encoding acyltransferase. Additionally provided is method for forming palmityl esters of glucose comprising reacting 1-O-palmitoyl-.beta.-D-glucose with itself, with glucose or with palmityl partial ester of glucose in the presence of a catalytically effective amount of acyltransferase.Type: GrantFiled: March 13, 1998Date of Patent: May 23, 2000Assignee: Cornell Research Foundation, Inc.Inventors: John C. Steffens, Gurdey S. Ghangas
-
Patent number: 5756328Abstract: Essentially pure acyltransferase is provided which is functional to catalyze reaction to form sugar esters. Also provided is isolated gene encoding acyltransferase. Additionally provided is method for forming palmityl esters of glucose comprising reacting 1-O-palmitoyl-.beta.-D-glucose with itself, with glucose or with palmityl partial ester of glucose in the presence of a catalytically effective amount of acyltransferase.Type: GrantFiled: June 21, 1996Date of Patent: May 26, 1998Assignee: Cornell Research Foundation, Inc.Inventors: John C. Steffens, Gurdev S. Ghangas
-
Patent number: 5550214Abstract: An isolated antigenic peptide fragment that is an isolated oncogene protein fragment is disclosed. The isolated peptide fragment of the invention is a peptide either 9 or 10 amino acid residues in length that includes at least a leucine residue at the C- terminus (i.e., position 9 or position 10). The peptide fragment is capable of binding in an HLA-A2 binding cleft and is capable of stimulating proliferation of at least one tumor-specific cytotoxic T-lymphocyte. Preferred peptides further include an isoleucine residue at position 2 and a valine residue at position 6. The most preferred isolated peptides can stimulate proliferation of cytotoxic T-lymphocytes obtainable from peripheral blood lymphocytes, ovarian tumors, breast tumors, gastric tumors, non-small cell lung tumors, pancreatic tumors, colon tumors, gliomas, bladder tumors, endometrial tumors and neuroblastomas. The preferred isolated peptide of the invention is a mutant peptide defined by SEQ ID NO.:2 or its functional equivalents.Type: GrantFiled: February 10, 1994Date of Patent: August 27, 1996Assignee: Brigham and Women's HospitalInventors: Timothy J. Eberlein, George E. Peoples, Ichiro Yoshino, Peter Goedegebuure